Abstract:Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide. Although epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have dramatically improved the life expectancy of patients with NSCLC, concerns about TKI-induced cardiotoxicities have increased. AC0010, a novel third-generation TKI, was developed to overcome drug resistance induced by EGFR-T790M mutation. However, the cardiotoxicity of AC0010 remains unclear. To evaluate the efficacy and cardiotoxicity of AC0010, we designed a novel multifunctional biosensor by integrating microelectrodes (MEs) and interdigital electrodes (IDEs) to comprehensively evaluate cell viability, electrophysiological activity, and morphological changes (beating of cardiomyocytes). The multifunctional biosensor can monitor AC0010-induced NSCLC inhibition and cardiotoxicity in a quantitative, label-free, noninvasive, and real-time manner. AC0010 was found to significantly inhibit NCI-H1975 (EGFR-L858R/T790M mutation), while weak inhibition was found for A549 (wild-type EGFR). Negligible inhibition was found in the viabilities of HFF-1 (normal fibroblasts) and cardiomyocytes. With the multifunctional biosensor, we found that 10 μM AC0010 significantly affected the extracellular field potential (EFP) and mechanical beating of cardiomyocytes. The amplitude of EFP continuously decreased after AC0010 treatment, while the interval decreased first and then increased. We analyzed the change in the systole time (ST) and diastole time (DT) within a beating interval and found that the DT and DT/beating interval rate decreased within 1 h after AC0010 treatment. This result probably indicated that the relaxation of cardiomyocytes was insufficient, which may further aggravate the dysfunction. Here, we found that AC0010 significantly inhibited EGFR-mutant NSCLC cells and impaired cardiomyocyte function at low concentrations (10 μM). This is the first study in which the risk of AC0010-induced cardiotoxicity was evaluated. In addition, novel multifunctional biosensors can comprehensively evaluate the antitumor efficacy and cardiotoxicity of drugs and candidate compounds.

A cardiomyocyte-based biosensor for antiarrhythmic drug evaluation by simultaneously monitoring cell growth and beating.

In Vitro Assessing the Risk of Drug-Induced Cardiotoxicity by Embryonic Stem Cell-Based Biosensor

Beating Cardiac Cell-Based Biosensor and Its Application in Drugs Screening

Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays

Cardiac Cell-based Biosensor and Its Biomedical Applications

Integrated Cell-Based Biosensor for Extracellular Electrophysiological Monitoring

Evolution Profile for Assessing Drug-Induced Arrhythmia Using Multifunctional Cardiomyocyte-Based Biosensor

Multifunctional Cardiomyocyte-Based Biosensor For Electrophysiology-Mechanical Beating-Growth Viability Monitoring

High-temporal-range Drug-Induced Cardiac Side-Effect Evaluation Using Simultaneous HL-1-based Impedance and Long-Term Electrophysiology Recording Systems

Evaluating the Efficacy and Cardiotoxicity of EGFR-TKI AC0010 with a Novel Multifunctional Biosensor

Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity

High-Throughput Assessment Of Drug Cardiac Safety Using A High-Speed Impedance Detection Technology-Based Heart-On-A-Chip

3D Cell-Based Biosensor for Cell Viability and Drug Assessment by 3D Electric Cell/matrigel-Substrate Impedance Sensing.

The Single-Cell Biosensor For Monitoring Extracellular Action Potential And Evaluating Drugs

A Biosensing System Using a Multiparameter Nonlinear Dynamic Analysis of Cardiomyocyte Beating for Drug-Induced Arrhythmia Recognition

Drug evaluations using a novel microphysiometer based on cell-based biosensors

Electromechanical Integrated Recording of Single Cardiomyocyte in Situ by Multimodal Microelectrode Biosensing System.

Universal and Sensitive Drug Assessment Biosensing Platform Using Optimal Mechanical Beating Detection of Single Cardiomyocyte

Cardiomyocyte electrical-mechanical synchronized model for high-content, dose-quantitative and time-dependent drug assessment

Synchronized High-Content Recording of Cardiomyocytes in Vitro by Integrated Cell-Based Biosensor

Efficacy and Cardiotoxicity Integrated Assessment of Anticancer Drugs by a Dual Functional Cell-Based Biosensor